Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA
- PMID: 40778752
- DOI: 10.1111/apt.70312
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA
Abstract
Background: Real-world data on dose escalation/de-escalation in inflammatory bowel disease (IBD) are scarce.
Aims: To assess the frequency, effectiveness and durability of escalation/de-escalation of infliximab, adalimumab, golimumab, vedolizumab and ustekinumab in IBD, and to identify factors influencing relapse and drug discontinuation and re-escalation efficacy.
Methods: We included patients from the ENEIDA registry of GETECCU who were exposed to biologics and analysed escalations/de-escalations. We assessed the impact of variables on durability, drug discontinuation and relapse after escalation/de-escalation.
Results: Of 19,720 patients on biologics, 5096 (26%) underwent dose escalation. Frequency of escalation per patient-year was 5% (infliximab), 7% (adalimumab), 7% (golimumab), 10% (vedolizumab) and 12% (ustekinumab). Clinical remission was recaptured in 32%-49% of patients. Durability of escalation (24 months) ranged from 66% to 88%. Drug discontinuation was associated with previous biologic exposure and disease duration (infliximab), monotherapy (adalimumab) and ulcerative colitis (ustekinumab). There were 669 de-escalations. The frequency per patient-year was 6%, 9%, 5%, 6% and 3% for infliximab, adalimumab, golimumab, vedolizumab and ustekinumab. Maintenance of remission after de-escalation was observed in 75%-100%. Durability of de-escalation (12 months) was 82%-90%. Factors associated with relapse were biologic exposure (infliximab) and age at de-escalation (adalimumab). Re-escalation benefited most patients.
Conclusions: In the long term, some patients with IBD need biologic escalation, which frequently recaptures durable clinical remission. De-escalation is feasible in some patients. Re-escalation is generally effective after relapse.
Keywords: biologics; dose escalation; inflammatory bowel disease.
© 2025 John Wiley & Sons Ltd.
References
-
- C. Gomez‐Labrador, E. Ricart, M. Iborra, et al., “Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA,” Pharmaceutics 16 (2024): 629.
-
- L. Guberna, O. P. Nyssen, M. Chaparro, and J. P. Gisbert, “Frequency and Effectiveness of Empirical Anti‐TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review With Meta‐Analysis,” Journal of Clinical Medicine 10 (2021): 2132.
-
- L. Peyrin‐Biroulet, S. Danese, M. Argollo, et al., “Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta‐Analysis,” Clinical Gastroenterology and Hepatology 17 (2019): 838–846.e2.
-
- E. Shmidt, G. Kochhar, J. Hartke, et al., “Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease,” Inflammatory Bowel Diseases 24 (2018): 2461–2467.
-
- R. S. Dalal, J. C. Pruce, and J. R. Allegretti, “Long‐Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases,” Inflammatory Bowel Diseases 29 (2022): 830–833.
Grants and funding
LinkOut - more resources
Full Text Sources